Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review

EJNMMI Research

Patrick Lugenbiel¹  Eberhard Scholz²  Frederik L. Giesel³  Uwe Haberkorn⁴  Sebastian Adeberg⁵  Jürgen Debus⁵  Daniel R. Zwahlen⁶  Paul Windisch⁶ 

[1] Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany;Heidelberg Center for Heart Rhythm Disorders (HCR), Heidelberg University Hospital, Heidelberg, Germany;Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany;Heidelberg Center for Heart Rhythm Disorders (HCR), Heidelberg University Hospital, Heidelberg, Germany;DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, University of Heidelberg, Heidelberg, Germany;Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany;Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany;Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany;National Center for Tumor Diseases (NCT), Heidelberg, Germany;Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany;Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;German Cancer Consortium (DKTK), Partner Site, Heidelberg, Germany;Department of Radiation Oncology, Kantonsspital Winterthur, Brauerstrasse 15, 8400, Winterthur, Switzerland;

关键词: Fibroblasts;    Fibroblast activation protein;    FAP;    Positron emission tomography;    PET;    PET-CT;   

DOI  :  10.1186/s13550-021-00761-2

来源: Springer

【 摘 要 】

PurposeSmall molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. While most of the existing literature has been focussed on the application of FAP-specific PET in various kinds of cancers, some researchers have, both intentionally or unintentionally, used FAP-specific PET in patients with non-cancerous diseases. The purpose of this systematic review is therefore to summarize the available evidence of FAP-specific PET for non-malignant indications.MethodsThe MEDLINE database was searched for studies presenting the clinical use of FAP-specific PET, the records were screened according to PRISMA guidelines and articles containing patients suffering from non-malignant diseases were included.ResultsSixteen studies with 303 patients were included. FAP-specific PET has been used in cardiac imaging, IgG4-related disease, benign tumors as well as various kinds of inflammation. Two prospective studies on FAP-specific PET for IgG4-related disease show its potential to differentiate inflammatory from fibrotic lesions, which could be used to determine the management of these patients.ConclusionWhile publications on FAP-specific PET for non-malignant indications are mostly limited to case reports and incidental findings, the first retrospective and prospective studies present promising results for IgG4-related as well as cardiovascular disease that warrant further research. Several currently recruiting trials will add to the body evidence in the next few years.

【 授权许可】

CC BY